Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company using artificial intelligence to discover and develop precision oncology therapies. Its lead asset, LP-300, is currently in a Phase 2 clinical trial targeting never-smoker non-small cell lung cancer (NSCLC), a patient population with no FDA-approved therapy specifically designed for them. On March 31, 2026, Lake Street Capital Markets reaffirmed a Buy rating and $25 price target on Lantern Pharma (NASDAQ: LTRN), implying upside of more than 1,400% from current levels. The near-term catalyst is a Type C meeting with the FDA scheduled for May 14, 2026.
| Recent Price | $3.88 |
| Market Cap | $49.50M |
| 52-Week Range | $1.11 - $5.7441 |
| Shares Outstanding | 12.76M |
| Volume | 1,503 |
| Insiders Ownership | 13.5% |
| Cash | $10.1 M |
| Institutional Ownership | 20% |
(Source: Stock Analysis)
The Market Backdrop: AI and Oncology Are Converging at Scale
The global AI in drug discovery market was valued at $2.35 billion in 2025 and is projected to reach $13.77 billion by 2033, growing at a CAGR of 24.8%. Oncology commands the largest share of that growth. The broader NSCLC treatment market, the disease space where Lantern Pharma's (NASDAQ: LTRN) lead drug competes, is projected to grow from $42.2 billion in 2025 to $70.81 billion by 2030, driven by targeted therapies and the rise of personalized medicine.
(Source: Research and Markets)
The biotech sector is entering 2026 with what analysts at Investing News Network describe as a "positive outlook, characterized by reasonable valuations, robust oncology momentum, and supportive policy tailwinds." FDA leadership has publicly signaled support for oncology and rare disease innovation, a dynamic that directly benefits companies like Lantern Pharma (NASDAQ: LTRN).
What Lantern Pharma (NASDAQ: LTRN) Actually Does
Lantern Pharma (NASDAQ: LTRN) is operating at the intersection of two of the fastest-growing areas in biopharma: AI-driven drug discovery and precision oncology.
(Source: Lantern Pharma Inc.)
The RADR® platform, Lantern Pharma’s proprietary AI Platform, ingests more than 200 billion oncology-focused data points across a library of 200+ machine learning algorithms. It identifies which patients are most likely to respond to a given drug candidate, before expensive late-stage development begins. According to the company, this has reduced early drug development costs by approximately 80% and cut the average time to Phase 1 trials by roughly 70%, with an average cost of just $1.0–$2.5 million per program from initial AI insight to first-in-human trial.
Beginning in late December 2025, Lantern Pharma (NASDAQ: LTRN) entered beta testing for withZeta.ai, described as the first multi-agentic AI co-scientist purpose-built for rare cancer drug discovery, with more than 25 biotech companies, cancer research centers, and biopharma consultants. The platform was officially launched in January 2026, and management has indicated a commercial subscription and usage-based revenue model is planned for 2026.
The Asset Behind the $25 Price Target
Lake Street's $25 valuation is built entirely on a single asset: LP-300.
LP-300 targets relapsed NSCLC in never-smokers, a $4 billion+ subset of the current $42.2 billion global addressable market, according to Lantern Pharma (NASDAQ: LTRN). As experts at OncLive have noted, never-smokers, particularly women, are increasingly being diagnosed with NSCLC, yet no drug has ever been specifically approved for this population. LP-300 is currently enrolling patients in the multinational HARMONIC™ Phase 2 trial, with Japan enrollment already completed ahead of schedule and promising early U.S. data reported.
Lake Street analyst Chad Messer projects LP-300 could generate more than $1.25 billion in combined annual sales across the U.S., Europe, and Asia by 2032. Applying a standard 5x revenue multiple to those regional forecasts and discounting back seven years at a 50% annual rate, a rate the analyst explicitly states reflects the risks of Phase 2 development, the model yields a $294 million enterprise value and a per-share price target of $25.
Critically, that price target assigns zero value to LP-184, LP-284, the ADC programs, or withZeta.ai. Each represents an upside that is not reflected in the base case.
The Catalyst: May 2026 FDA Type C Meeting
The most significant near-term event for Lantern Pharma (NASDAQ: LTRN) is a Type C meeting with the FDA scheduled for May 14, 2026.
Lantern Pharma (NASDAQ: LTRN) has submitted a package seeking FDA concurrence on three amendments to the HARMONIC™ trial protocol:
- Narrowing enrollment to patients with the EGFR exon 21 L858R mutation, a subgroup showing higher clinical benefit in preliminary data
- Extending maximum treatment from six cycles to eight
- Converting to a single-arm Simon two-stage design to address enrollment challenges created by the emergence of new treatment options in the control arm
If the FDA concurs, these changes are expected to accelerate enrollment and bring the trial to a meaningful data readout faster, a potential re-rating event for Lantern Pharma (NASDAQ: LTRN) shares.
A Pipeline Advancing Across Multiple Fronts
While LP-300 is the headline, the rest of Lantern Pharma's (NASDAQ: LTRN) pipeline has continued to achieve key milestones.
(Source: Lantern Pharma Inc.)
LP-184 completed its Phase 1a trial with all primary endpoints met and a 48% clinical benefit rate at or above the therapeutic dose threshold. As a result, a recommended Phase 2 dose of 0.39 mg/kg was established. Phase 1b/2 trials are planned in triple-negative breast cancer, NSCLC, and bladder cancer in 2026, subject to funding."
LP-284 received a third FDA Orphan Drug Designation in January 2026 for soft tissue sarcomas, adding to existing designations for mantle cell lymphoma and high-grade B-cell lymphomas. Early Phase 1 data has shown a complete metabolic response in a heavily pre-treated diffuse large B-cell lymphoma patient who had previously failed CAR-T therapy and bispecific antibody treatment.
(Source: Lantern Pharma Inc.)
Through its wholly-owned subsidiary Starlight Therapeutics, Lantern Pharma (NASDAQ: LTRN) received FDA IND clearance in early 2026 for a planned Phase 1 pediatric CNS cancer trial of STAR-001. Lake Street notes this program holds Rare Pediatric Disease and Orphan Drug Designations, which could qualify Lantern Pharma (NASDAQ: LTRN) for a Priority Review Voucher upon approval, a regulatory asset that has historically traded for hundreds of millions of dollars.
What the Bull Case Requires, And What Could Stand in the Way
Lantern Pharma (NASDAQ: LTRN) is not without the risks typical of clinical-stage drug development. While LP-300 has not succeeded in prior Phase 3 studies, two of those trials produced meaningful efficacy signals in the never-smoker population, the very data that forms the scientific foundation for the HARMONIC™ trial today.
The pipeline has yet to receive regulatory approval, and the company will likely need to raise additional capital to see LP-300 through to commercialization. Notably, Lake Street's model already accounts for these uncertainties through a steep 50% annual discount rate, one of the more conservative assumptions used in biotech valuation, and still arrives at a $25 price target.
The Investment Imperative
Lantern Pharma's (NASDAQ: LTRN) market capitalization of approximately $17.9 million sits well below what Lake Street's model implies even under conservative assumptions. The company finds itself at a critical inflection point, with its most advanced asset approaching a key regulatory milestone, a completed Phase 1a readout for its second clinical program, and a newly launched AI platform already in commercial beta testing with dozens of external partners.
For investors willing to accept the binary risks inherent in clinical-stage drug development, the current entry point offers a significant gap between the stock's trading price and the analyst's assessed value, driven by a single asset, with the rest of the pipeline priced at zero.
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. Lantern Pharma (LTRN) is a client of RedChip Companies, Inc. LTRN agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock for six months of investor awareness services, beginning in March 2026. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. Previously, LTRN agreed to pay RedChip an $8,500 monthly cash fee, beginning in June 2025, for three months of investor awareness services, and a $10,000 monthly cash fee, beginning in April 2023, and 2500 shares of Rule 144 stock, for six months of RedChip investor awareness services. The shares were registered and RedChip sold its shares immediately. LTRN also agreed to pay RedChip a one-time $54,000 fee for a 10-day national TV ad campaign aired in June 2025. LTRN also agreed to pay RedChip a $104,000 fee for a six week national TV ad campaign aired weekdays from February 26 through April 15, 2024. RedChip’s president purchased 50,000 shares of LTRN stock at $1.27 per share in March 2026; these shares may be sold at any time, and you may be buying as they are sold. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.